First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 833 000 KRW -0.36% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. [ Read More ]

The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 415 278.78 KRW. Compared to the current market price of 833 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.

Key Points:
Intrinsic Value
Base Case
415 278.78 KRW
Overvaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Samsung Biologics Co Ltd

Backtest Samsung Biologics Co Ltd Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Samsung Biologics Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Samsung Biologics Co Ltd

Current Assets 5.4T
Cash & Short-Term Investments 1.8T
Receivables 895.4B
Other Current Assets 2.7T
Non-Current Assets 10.5T
Long-Term Investments 39B
PP&E 4.3T
Intangibles 5.9T
Other Non-Current Assets 291.8B
Current Liabilities 4.1T
Accounts Payable 164.5B
Accrued Liabilities 284.3B
Short-Term Debt 509.5B
Other Current Liabilities 3.1T
Non-Current Liabilities 2.2T
Long-Term Debt 487.6B
Other Non-Current Liabilities 1.7T
Efficiency

Earnings Waterfall
Samsung Biologics Co Ltd

Revenue
3.7T KRW
Cost of Revenue
-1.9T KRW
Gross Profit
1.8T KRW
Operating Expenses
-689.1B KRW
Operating Income
1.1T KRW
Other Expenses
-256B KRW
Net Income
857.7B KRW

Free Cash Flow Analysis
Samsung Biologics Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Samsung Biologics Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive Operating Income
Positive Net Income
59/100
Profitability
Score

Samsung Biologics Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Samsung Biologics Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Low D/E
Long-Term Solvency
82/100
Solvency
Score

Samsung Biologics Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Samsung Biologics Co Ltd

Wall Street analysts forecast Samsung Biologics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 036 354.03 KRW with a low forecast of 757 500 KRW and a high forecast of 1 312 500 KRW.

Lowest
Price Target
757 500 KRW
9% Downside
Average
Price Target
1 036 354.03 KRW
24% Upside
Highest
Price Target
1 312 500 KRW
58% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Samsung Biologics Co Ltd

1M 1M
+4%
6M 6M
+21%
1Y 1Y
+5%
3Y 3Y
+13%
5Y 5Y
+163%
10Y 10Y
+485%
Annual Price Range
833 000
52w Low
680 000
52w High
859 000
Price Metrics
Average Annual Return 32.25%
Standard Deviation of Annual Returns 44.32%
Max Drawdown -34%
Shares Statistics
Market Capitalization 59.3T KRW
Shares Outstanding 71 174 000
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd

Country

Korea

Industry

Life Sciences Tools & Services

Market Cap

59.3T KRW

Dividend Yield

0%

Description

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company is headquartered in Incheon, Incheon. The company went IPO on 2016-11-10. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. The company also provides cell line development and process development services. The firm distributes its products in domestic and overseas markets.

Contact

INCHEON
Incheon
300, Songdo bio-daero, Yeonsu-gu
+82324553114
https://samsungbiologics.com/

IPO

2016-11-10

Employees

-

Officers

CEO, President & Chairman of Board
Mr. John Chongbo Rim
CFO, Executive VP, MD & Director
Mr. Dong-Joong Kim
Executive Director
Dr. Tae-Han Kim Ph.D.
Executive VP and Head of Bio R&D Centre & CSO
Dr. Namjin Chung Ph.D.
Vice President & Head of Legal Compliance Team
Mr. Hyung Woo Moon
Executive VP, Chief Marketing Officer & Head of Sales Support Center
Mr. James J. Choi
Show More
Vice President, CHRO & Head of HR Support Center
Mr. Yong Park
Executive VP & Head of CDO Development Center
Dr. Brian Hosung Min Ph.D.
VP & Head of Business Consulting Team
Mr. Heekyun Lim
Executive VP & Head of EPCV Center
Dr. Kun Lo Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one Samsung Biologics Co Ltd stock?

The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 415 278.78 KRW.

Is Samsung Biologics Co Ltd stock undervalued or overvalued?

Compared to the current market price of 833 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.